OrbiMed, a leading global healthcare investment firm, raised $3 billion in commitments across two new private equity funds:
– OrbiMed Private Investments X: Over $1.9 billion to invest in U.S. and European life sciences venture capital opportunities.
– OrbiMed Asia Partners VI: Over $1 billion to invest in healthcare growth equity and venture capital opportunities across Asia.
Both funds target the development of leading healthcare companies across biopharmaceuticals, medical devices, diagnostics and technology-enabled healthcare services.
Carl Gordon, Managin Partner, highlighted the growing investment opportunities driven by AI, new therapeutic modalities and China’s emergence as a biotechnology powerhouse.
OrbiMed is led by 20 partners and supported by more than 150 professionals specializing in company incubation, strategy, operations and finance.
The firm operates from 12 global locations across key healthcare markets.
Investors in the new funds include medical institutions, university endowments, foundations, pension funds, sovereign wealth funds and family offices.
Carter Neild, Managing Partner, thanked the firm’s long-standing investors for their continued support and reaffirmed OrbiMed’s commitment to meeting their expectations.
